Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loteprednol Etabonate Base vs Suspension in Allergic Conjunctivitis
NCT01107405Phase 2Completed
- Sponsor
- Bausch + Lomb
- Start
- Apr 2010
- Primary completion
- May 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of loteprednol etabonate ophthalmic gel 0.38% in allergic conjunctivitis (AC), sponsored by Bausch + Lomb. Started Apr 2010; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01107405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01107405.